Continual reassessment method for partial ordering

Biometrics

Volumn 67, Issue 4, 2011, Pages 1555-1563

  Wages, Nolan A ^a   Conaway, Mark R ^b   O'Quigley, John ^c  

^a HAMPDEN SYDNEY COLLEGE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c INSERM   (France)

Author keywords

Clinical trial; Continual reassessment method; Dose escalation; Dose finding studies; Drug combination; Maximum tolerated dose; Partial ordering; Phase 1 trials; Toxicity

Indexed keywords

BIOMETRICS; DRUG DOSAGE; MULTI AGENT SYSTEMS;

CLINICAL TRIAL; CONTINUAL REASSESSMENT METHOD; DOSE ESCALATION; DOSE FINDING; DOSE-FINDING STUDY; DRUG COMBINATIONS; MAXIMUM TOLERATED DOSE; PARTIAL ORDER; PHASE 1; PHASE 1 TRIAL;

TOXICITY;

ASSESSMENT METHOD; DESIGN; DOSE-RESPONSE RELATIONSHIP; DRUG; ESTIMATION METHOD; EXPERIMENTAL STUDY; STATISTICAL ANALYSIS; TOLERANCE; TWO-DIMENSIONAL MODELING;

EID: 80051700104     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2011.01560.x     Document Type: Article

References (19)

1. Berenson, J. R., Yellin, O., Patel, R., Duvivier, H., Nassir, Y., Mapes, R., Abaya, C. D., and Swift, R. A. (2009). A phase I study of Samarium Lexidronam/Bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research 15, 1069-1075.
2. Cheung, Y. K. (2005). Coherence principles in dose-finding studies. Biometrika 92, 863-873.
3. Conaway, M., Dunbar, S., and Peddada, S. (2004). Designs for single- or multiple-agent phase I trials. Biometrics 60, 661-669.
4. Dunbar, S., Conaway, M., and Peddada, S. (2001). On improved estimation of parameters subject to order restrictions. Statistics and Applications 3, 121-128.
5. Huang, X., Biswas, S., Oki, Y., Issa, J. P., and Berry, D. A. (2007). A parallel phase I/II clinical trial design for combination therapies. Biometrics 63, 429-436.
6. Hwang, J. and Peddada, S. (1994). Confidence interval estimation subject to order restrictions. Annals of Statistics 22, 67-93.
7. Korn, E. L. and Simon, R. (1993). Using tolerable-dose diagrams in the design of phase I combination chemotherapy trials. Journal of Clinical Oncology 11, 794-801.
8. Kramar, A., Lebecq, A., Candalh, E. (1999). Continual reassessment methods in phase I trials of the combination of two agents in oncology. Statistics in Medicine 18, 1849-1864.
9. Lee, S. M. and Cheung, Y. K. (2009). Model calibration in the continual reassessment method. Journal of the Society for Clinical Trial 6, 227-238.
10. O'Quigley, J. and Shen, L. Z. (1996). Continual reassessment method: A likelihood approach. Biometrics 52, 163-174.
11. O'Quigley, J., Pepe, M., and Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46, 33-48.
12. Q'Quigley, J., Paoletti, X., and Maccario, J. (2002). Nonparametric optimal design in dose finding studies. Biostatistics 3, 51-56.
13. Robertson, T., Wright, F., and Dykstra, R. (1988). Order Restricted Statistical Inference. New York: Wiley.
14. Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics 45, 925-937.
15. Thall, P. F., Milliken, R., Mueller, P., and Lee, S.-J. (2003). Dose-finding with two agents in phase I oncology trials. Biometrics 59, 487-496.
16. Wang, K. and Ivanova, A. (2005). Two-dimensional dose finding in discrete dose space. Biometrics 61, 217-222.
17. Yin, G. and Yuan, Y. (2009a). Bayesian dose finding for drug combinations by copula regression. Journal of the Royal Statistical Society 58, 211-224.
18. Yin, G. and Yuan, Y. (2009b). A latent contingency table approach to dose-finding for combinations of two agents. Biometrics 65, 866-875.
19. Yuan, Y. and Yin, G. (2008). Sequential continual reassessment method for two-dimensional dose-finding. Statistics in Medicine 27, 5664-5678.